Arena Pharmaceuticals (ARNA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA)

ARNA 99.99

0.0%

Mar 15 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Harold Engstrom	4/20/2018 10:03:04 PM
	Read Replies (1) of 2274

The P2a APD371 trial (full CB agonist) has been talked about by both the CEO and by analysts more than it should be unless the open label results are looking strong. The trial is only 20 patients with CD... but now on CNBC (power lunch) and on Bloomberg radio, the CEO has been interviewed and APD371 has come up. IMO, these short interviews are scripted...so...is there is a reason APD371 is being asked about? And Fast Money mentioned APD371, too, on Thursday. All of a sudden this potential neuropathic pain miracle drug is getting more attention than a drug that hasn’t reported open label P2a results should get. Fire under that smoke? Hope so.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next